Insider Buying: Inovio Pharmaceuticals Inc (NASDAQ:INO) Insider Acquires 20,000 Shares of Stock

Inovio Pharmaceuticals Inc (NASDAQ:INO) insider Laurent Humeau bought 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The shares were acquired at an average price of $2.50 per share, for a total transaction of $50,000.00. Following the completion of the transaction, the insider now owns 45,833 shares in the company, valued at $114,582.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Inovio Pharmaceuticals stock traded up $0.02 during mid-day trading on Friday, hitting $2.94. 1,867,806 shares of the stock were exchanged, compared to its average volume of 1,567,792. The company has a quick ratio of 4.92, a current ratio of 4.92 and a debt-to-equity ratio of 1.02. Inovio Pharmaceuticals Inc has a 12 month low of $2.15 and a 12 month high of $6.30. The firm’s fifty day moving average price is $2.88. The firm has a market capitalization of $286.26 million, a PE ratio of -2.80 and a beta of 1.96.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.01). The company had revenue of $2.83 million during the quarter, compared to the consensus estimate of $4.44 million. Inovio Pharmaceuticals had a negative net margin of 295.24% and a negative return on equity of 97.95%. On average, analysts forecast that Inovio Pharmaceuticals Inc will post -1.01 earnings per share for the current year.

INO has been the topic of several recent research reports. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Maxim Group restated a “buy” rating and set a $8.00 price target on shares of Inovio Pharmaceuticals in a report on Wednesday, April 3rd. BidaskClub upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, May 10th. Finally, Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $7.22.

Large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new stake in shares of Inovio Pharmaceuticals in the 1st quarter valued at $40,000. Quantamental Technologies LLC bought a new stake in shares of Inovio Pharmaceuticals in the 4th quarter valued at $43,000. Amalgamated Bank bought a new stake in shares of Inovio Pharmaceuticals in the 4th quarter valued at $50,000. M Holdings Securities Inc. bought a new stake in shares of Inovio Pharmaceuticals in the 1st quarter valued at $54,000. Finally, Paloma Partners Management Co increased its stake in shares of Inovio Pharmaceuticals by 38.7% in the 4th quarter. Paloma Partners Management Co now owns 16,201 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 4,522 shares in the last quarter. Institutional investors own 47.24% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Featured Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Insider Buying and Selling by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.